**Specifications table**TableSubject areaClinical and Translational ResearchMore specific subject areaBiomarker Research, Cancer EpidemiologyType of dataTablesHow data was acquiredThe TYBRES study was designed to assess the relationship between utilization of specific diabetes mellitus pharmacotherapies, breast cancer outcomes, and biomarker profiles, of which the associations between medication use and adipokines' circulation have been recently reported [@bib1], [@bib2]. The data presented here was obtained by linking new biomarker profiles to the original TYBRES patient database. Tumor registry query was followed by vital status ascertainment, and medical records review as described [@bib1], [@bib2].\
Luminex®-based quantitation from plasma samples was conducted for the following inflammatory C--C chemokine ligands: Chemokine ligand 2, CCL-2 (monocyte chemoattractant protein 1, MCP-1); chemokine ligand 3, CCL-3 (macrophage inflammatory protein 1α, MIP-1α); chemokine ligand 4, CCL-4 (macrophage inflammatory protein 1β, MIP-1β); and chemokine ligand 5, CCL-5 (regulated on activation normal T cell expressed and secreted, RANTES).\
A Luminex®200™ instrument with Xponent 3.1 software was used to acquire all dataData formatAnalyzedExperimental factorsAbove described biomarkers were determined from the corresponding plasma samples collected at the time of breast cancer diagnosis.Experimental featuresThis dataset included 97 adult female cases diagnosed with type 2 diabetes and incident breast cancer and 194 matched controls with newly diagnosed breast cancer, but no diabetes diagnosis. Clinical and treatment history were evaluated in relationship with cancer outcomes and C-C chemokine profiles. A correlation analysis was performed.Data source locationUnited States, Buffalo, NY -- 42° 53′ 50.3592″N; 78° 52′ 2.658″WData accessibilityThe data is with this article

**Value of the data**•Monocytes' mobilization to the tumor location is a chemotactic response mediated by pro-inflammatory C--C chemokine ligands: CCL-2, CCL-3, CCL-4, and CCL-5 [@bib3]. Their combined contribution determines specific tumor environment changes many of which are responsible for metastasis.•CCL-2 was the first described tumor-derived factor while later has been found to also be elevated among type 2 diabetes patients [@bib4], [@bib5]. CCL-2 promotes tumor metastasis through secretion of CCL-3. Given its crucial role, CCl-2 is currently explored as a diagnostic and prognostic biomarker [@bib6], [@bib7], [@bib8], [@bib9]. CCL-4 and CCL-5 are reported to facilitate metastasis and contribute to disease progression [@bib10], [@bib11], [@bib12]. CCL-5 is currently considered as a therapeutic target for breast cancer [@bib13]•Present data shows the observed relationship between history of insulin secretagogue use, circulating C--C chemokines at breast cancer diagnosis and cancer outcomes.•This data provides additional detail for the design of future studies investigating the relationship between insulin production and inflammation leading to breast cancer metastasis.•Our observations have the potential to guide research investigating the use of C--C chemokines as diagnostic and/or prognostic indicators.

1. Data {#s0005}
=======

Reported data represents the observed association between use of insulin secretagogues preceding breast cancer and the inflammatory C--C chemokine profiles at the time of cancer diagnosis in women with diabetes mellitus ([Table 1](#t0005){ref-type="table"}). Data in [Table 2](#t0010){ref-type="table"} includes the observed correlations between the measured biomarkers stratified by type 2 diabetes mellitus pharmacotherapy and controls, as well as correlations with other inflammatory adipokines reported by us in the past: tumor necrosis factor α, interleukin 1β and its receptor antagonist, and interleukin 6. The details regarding tumor necrosis factor α, interleukin 1β and its receptor antagonist, and interleukin 6 determination from plasma, their association with cancer outcomes and use of insulin secretagogues has been previously reported [@bib1], [@bib2].

2. Experimental design, materials and methods {#s0010}
=============================================

Evaluation of pro-inflammatory cytokine profiles association with insulin secretagogue use and BC outcomes was carried out under two protocols approved by both Roswell Park Cancer Institute (EDR154409 and NHR009010) and the State University of New York at Buffalo (PHP0840409E). Demographic and clinical patient information was linked with cancer outcomes and pro-inflammatory cytokine profiles of corresponding plasma specimen harvested at BC diagnosis and banked in the Roswell Park Cancer Institute Data Bank and Bio-Repository.

2.1. Study population {#s0015}
---------------------

All incident breast cancer cases diagnosed at Roswell Park Cancer Institute (01/01/2003--12/31/2009) were considered for inclusion (*n*=2194). Medical and pharmacotherapy history were used to determine the baseline presence of diabetes [@bib1], [@bib2].

2.2. Inclusion and exclusion criteria {#s0020}
-------------------------------------

All adult women with pre-existing diabetes at breast cancer diagnosis having available banked treatment-naïve plasma specimens (blood collected prior to initiation of any cancer-related therapy -- surgery, radiation or pharmacotherapy) in the Institute׳s Data Bank and Bio-Repository were included.

Subjects were excluded if they had prior cancer history or unclear date of diagnosis, incomplete clinical records, type 1 or unclear diabetes status. For a specific breakdown of excluded subjects, please see the original research article by Wintrob et al. [@bib1].

A total of 97 female subjects with breast cancer and baseline diabetes mellitus were eligible for inclusion in this analysis.

2.3. Control-matching approach {#s0025}
------------------------------

Each of the 97 adult female subjects with breast cancer and diabetes mellitus (defined as "cases") was matched with two other female subjects diagnosed with breast cancer, but without baseline diabetes mellitus (defined as "controls"). The following matching criteria were used: age at diagnosis, body mass index category, ethnicity, menopausal status and tumor stage (as per the American Joint Committee on Cancer). Some matching limitations applied [@bib1].

2.4. Demographic and clinical data collection {#s0030}
---------------------------------------------

Clinical and treatment history was documented as previously described [@bib1]. Vital status was obtained from the Institute׳s Tumor Registry, a database updated biannually with data obtained from the National Comprehensive Cancer Networks' Oncology Outcomes Database. Outcomes of interest were breast cancer recurrence and/or death. The specific treatment groups have been defined according to the mechanism of action of their respective diabetes pharmacotherapy. Receiving any of the following pharmacotherapies alone or in combination: sulfonylureas (glimepiride, glipizide, and glyburide), meglitinides (nateglinide, repaglinide), alpha-glucosidase inhibitors (acarbose, miglitol), glucagon-like peptide-1 receptor agonists (exenatide, liraglutide), led to assigning the subject to the "any secretagogue" user group, whereas the "no secretagogue" user group included patients receiving one or more of the following treatment options: biguanides (metformin) and thiazolidinediones (pioglitazone, rosiglitazone) or no oral pharmacotherapy [@bib1]. Of note is that each of the two groups, *any secretagogue* and *no secretagogue*, included 11 and respectively 9 insulin users.

2.5. Plasma specimen storage and retrieval {#s0035}
------------------------------------------

All the plasma specimens retrieved from long-term storage were individually aliquoted in color coded vials labeled with unique, subject specific barcodes. Overall duration of freezing time was accounted for all matched controls ensuring that the case and matched control specimens had similar overall storage conditions. Only two instances of freeze-thaw were allowed between biobank retrieval and biomarker analyses: aliquoting procedure step and actual assay.

2.6. Luminex® assays {#s0040}
--------------------

A total of 5 biomarkers -- chemokine ligand 2, CCL-2 (monocyte chemoattractant protein 1, MCP-1); chemokine ligand 3, CCL-3 (macrophage inflammatory protein 1α, MIP-1α); chemokine ligand 4, CCL-4 (macrophage inflammatory protein 1β, MIP-1β); and chemokine ligand 5, CCL-5 (regulated on activation normal T cell expressed and secreted, RANTES) -- were quantified according to the manufacturer protocol. The HCYTOMAG-60K Luminex® biomarker panel (Millipore Corporation, Billerica, MA) was utilized in this study. Tumor necrosis factor α, interleukin 1β, interleukin 1β receptor antagonist, interleukin 6, and interleukin 10 determinations were done according to the manufacturer protocol as previously reported [@bib1], [@bib2].

2.7. Biomarker-pharmacotherapy association analysis {#s0045}
---------------------------------------------------

Biomarker cut-point optimization was performed for each analyzed biomarker. Biomarker levels constituted the continuous independent variable that was subdivided into two groups that optimized the log rank test among all possible cut-point selections yielding a minimum of 10 patients in any resulting group. Quartiles were also constructed. The resultant biomarker categories were then tested for association with type 2 diabetes mellitus therapy and controls by Fisher׳s exact test. The continuous biomarker levels were also tested for association with diabetes therapy and controls across groups by the Kruskal--Wallis test and pairwise by the Wilcoxon rank sum. Multivariate adjustments were performed accounting for age, tumor stage, body mass index, estrogen receptor status, and cumulative comorbidity. The biomarker analysis was performed using R Version 2.15.3. Please see the original article for an illustration of the analysis workflow [@bib1].

Correlations between biomarkers stratified by type 2 diabetes mellitus pharmacotherapy and controls were assessed by the Pearson method. Correlation models were constructed both with and without adjustment for age, body mass index, and the combined comorbidity index. Correlation analyses were performed using SAS Version 9.4.
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###### 

Pro-inflammatory Cytokine Associations with Secretagogue Use.

Table 1

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biomarker                                                 Biomarker grouping                                      Concentration   Control          No secretagogue   Any secretagogue   Unadjusted *p*-value (MVP)                       
  --------------------------------------------------------- ------------------------------------------------------- --------------- ---------------- ----------------- ------------------ ---------------------------- --------- --------- ---------
  CCL-2\                                                    Median\                                                 --              304\             296\              301\               0.810\                       1.000\    0.900\    0.970\
  (MCP-1, pg/ml)                                            (25th--75th)                                                            (221--392)       (252--382)        (216--391)         (0.610)                      (0.520)   (0.330)   (0.710)

  Quartiles                                                 1.6 to 225.6                                            52 (26.9%)      8 (17.0%)        13 (26.0%)        0.180              0.900                        0.620     0.540     

  227.7 to 302.5                                            42 (21.8%)                                              17 (36.2%)      13 (26.0%)                                                                                             

  303.7 to 388.6                                            50 (25.9%)                                              11 (23.4%)      11 (22.0%)                                                                                             

  391.9 to 4531.2                                           49 (25.4%)                                              11 (23.4%)      13 (26.0%)                                                                                             

  OS-Based\                                                 **1.6 to 395.8**[⁎](#tbl1fnstar){ref-type="table-fn"}   146 (75.6%)     36 (76.6%)       38 (76.0%)        0.890\             0.960\                       0.950\    0.990\    
  Optimization                                                                                                                                                         (0.610)            (0.550)                      (0.880)   (0.850)   

  398.5 to 4531.2                                           47 (24.4%)                                              11 (23.4%)      12 (24.0%)                                                                                             

  DFS-Based\                                                1.6 to 170.4                                            22 (11.4%)      3 (6.4%)         6 (12.0%)         0.430\             0.910\                       0.490\    0.580\    
  Optimization                                                                                                                                                         (0.100)            (0.480)                      (0.390)   (0.330)   

  **172.4 to 4531.2**                                       171 (88.6%)                                             44 (93.6%)      44 (88.0%)                                                                                             

                                                                                                                                                                                                                                             

  CCL-3\                                                    Median\                                                 --              3.82\            5.63\             3.86\              0.051\                       0.760\    0.230\    0.160\
  (MIP-1α, ng/ml)                                           (25th--75th)                                                            (2.38--6.95)     (3.18--10.09)     (1.97--9.11)       (0.160)                      (0.880)   (0.320)   (0.290)

  Quartiles                                                 0.36 to 2.37                                            49 (25.3%)      9 (19.1%)        15 (30.0%)        0.160              0.360                        0.540     0.280     

  2.41 to 4.02                                              53 (27.3%)                                              9 (19.1%)       11 (22.0%)                                                                                             

  4.07 to 7.96                                              51 (26.3%)                                              12 (25.5%)      9 (18.0%)                                                                                              

  8.11 to 390.27                                            41 (21.1%)                                              17 (36.2%)      15 (30.0%)                                                                                             

  OS-Based\                                                 0.36 to 4.02                                            102 (52.6%)     18 (38.3%)       26 (52.0%)        0.080\             0.940\                       0.180\    0.210\    
  Optimization                                                                                                                                                         (0.080)            (0.450)                      (0.350)   (0.180)   

  **4.07 to 390.27**[⁎](#tbl1fnstar){ref-type="table-fn"}   92 (47.4%)                                              29 (61.7%)      24 (48.0%)                                                                                             

  DFS-Based\                                                0.36 to 4.02                                            102 (52.6%)     18 (38.3%)       26 (52.0%)        0.080\             0.940\                       0.180\    0.210\    
  Optimization                                                                                                                                                         (0.080)            (0.450)                      (0.350)   (0.180)   

  **4.07 to 390.27**                                        92 (47.4%)                                              29 (61.7%)      24 (48.0%)                                                                                             

                                                                                                                                                                                                                                             

  CCL-4\                                                    Median\                                                 --              23.00\           28.74\            27.48\             0.009\                       0.060\    0.380\    0.012\
  (MIP-1β, pg/ml)                                           (25th--75th)                                                            (16.54--32.87)   (20.74--44.77)    (20.20--37.74)     (0.009)                      (0.250)   (0.380)   (0.019)

  Quartiles                                                 1.60 to 17.56                                           56 (28.9%)      8 (17.0%)        9 (18.0%)         0.220              0.370                        0.950     0.370     

  17.58 to 23.77                                            48 (24.7%)                                              11 (23.4%)      14 (28.0%)                                                                                             

  23.92 to 34.81                                            48 (24.7%)                                              12 (25.5%)      12 (24.0%)                                                                                             

  34.94 to 660.94                                           42 (21.6%)                                              16 (34.0%)      15 (30.0%)                                                                                             

  OS-Based\                                                 1.60 to 12.40                                           18 (9.3%)       3 (6.4%)         3 (6.0%)          0.770\             0.580\                       1.000\    0.770\    
  Optimization                                                                                                                                                         (0.370)            (0.230)                      (0.870)   (0.460)   

  **12.58 to 660.94**                                       176 (90.7%)                                             44 (93.6%)      47 (94.0%)                                                                                             

  DFS-Based\                                                1.60 to 13.59                                           26 (13.4%)      4 (8.5%)         3 (6.0%)          0.370\             0.160\                       0.710\    0.270\    
  Optimization                                                                                                                                                         (0.390)            (0.190)                      (0.810)   (0.360)   

  **13.69 to 660.94**                                       168 (86.6%)                                             43 (91.5%)      47 (94.0%)                                                                                             

                                                                                                                                                                                                                                             

  CCL-5\                                                    Median\                                                 --              7158\            5802\             5673\              0.640\                       0.090\    0.300\    0.230\
  (RANTES, pg/ml)                                           (25th--75th)                                                            (3460--14543)    (4168--10391)     (3269--8904)       (0.810)                      (0.240)   (0.220)   (0.400)

  Quartiles                                                 0 to 3446                                               49 (25.3%)      8 (17.0%)        16 (32.0%)        0.051              0.330                        0.350     0.110     

  3500 to 6307                                              41 (21.1%)                                              18 (38.3%)      14 (28.0%)                                                                                             

  6381 to 13442                                             48 (24.7%)                                              13 (27.7%)      11 (22.0%)                                                                                             

  13442 to 57898                                            56 (28.9%)                                              8 (17.0%)       9 (18.0%)                                                                                              

  OS-Based\                                                 0 to 3183                                               42 (21.6%)      8 (17.0%)        11 (22.0%)        0.480\             0.960\                       0.540\    0.770\    
  Optimization                                                                                                                                                         (0.650)            (0.810)                      (0.770)   (0.860)   

  **3212 to 57898**[⁎](#tbl1fnstar){ref-type="table-fn"}    152 (78.4%)                                             39 (83.0%)      39 (78.0%)                                                                                             

  DFS-Based\                                                0 to 16821                                              160 (82.5%)     43 (91.5%)       46 (92.0%)        0.140\             0.110\                       1.000\    0.100\    
  Optimization                                                                                                                                                         (0.029)            (0.160)                      (0.910)   (0.080)   

  **16982 to 57898**                                        34 (17.5%)                                              4 (8.5%)        4 (8.0%)                                                                                               
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Overall survival (OS)- and disease-free survival (DFS)-optimized biomarker ranges associated with poorer outcomes are represented in bold. Unadjusted *p*-values: p1, compares *no insulin versus control*; p2, compares *any insulin versus control*; p3, compares *any insulin versus no insulin* (as per Kruskal--Wallis test); global test, compares *all categories* (as per Wilcoxon, type 3 error test); MVP, denotes the *p*-value of each multivariate adjusted analysis corresponding to the earlier described unadjusted analyses. For more information, please see [Section 2.7](#s0045){ref-type="sec"} below and our previously published analysis work flow \[1\]. MVP=*p*-value of the multivariate adjusted analysis. Chemokine ligand 2, CCL-2 (monocyte chemoattractant protein 1, MCP-1); chemokine ligand 3, CCL-3 (macrophage inflammatory protein 1α, MIP-1α); chemokine ligand 4, CCL-4 (macrophage inflammatory protein 1β, MIP-1β); chemokine ligand 5, CCL-5 (regulated on activation normal T cell expressed and secreted, RANTES).

###### 

Pro-inflammatory Cytokine Correlations by Secretagogue Use.

Table 2

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compared biomarkers         Group        Unadjusted correlation     Adjusted correlation                                                                                          
  --------------------------- ------------ -------------------------- ---------------------- ---------------------- -------------------------- ------------- ---------------------- -------------
  CCL-2\                      CCL-3\       All subjects (*n*=291)     −0.042                 −0.156 to 0.074        0.480                      −0.043        −0.158 to 0.073        0.463
  (MCP-1)                     (MIP-1α)                                                                                                                                              

  Controls (*n*=194)          −0.034       −0.174 to 0.108            0.636                  −0.029                 −0.170 to 0.114            0.695                                

  No secretagogue (*n*=43)    −0.091       −0.381 to 0.215            0.560                  −0.125                 −0.420 to 0.194            0.440                                

  Any secretagogue (*n*=54)   −0.162       −0.412 to 0.110            0.238                  −0.158                 −0.416 to 0.122            0.263                                

                                                                                                                                                                                      

  CCL-2\                      CCL-4\       All subjects (*n*=291)     0.008                  −0.107 to 0.123        0.897                      0.008         −0.108 to 0.123        0.892
  (MCP-1)                     (MIP-1β)                                                                                                                                              

  Controls (*n*=194)          −0.002       −0.143 to 0.139            0.974                  −0.001                 −0.143 to 0.141            0.990                                

  No secretagogue (*n*=43)    0.057        −0.248 to 0.351            0.716                  0.048                  −0.268 to 0.354            0.768                                

  Any secretagogue (*n*=54)   0.078        −0.194 to 0.339            0.574                  0.082                  −0.198 to 0.350            0.564                                

                                                                                                                                                                                      

  CCL-2\                      CCL-5\       All subjects (*n*=291)     **−0.172**             **−0.281 to −0.058**   **0.003**                  **−0.174**    **−0.283 to −0.059**   **0.003**
  (MCP-1)                     (RANTES)                                                                                                                                              

  Controls (*n*=194)          **−0.257**   **−0.384 to −0.121**       **\<0.001**            **−0.251**             **−0.379 to −0.113**       **\<0.001**                          

  No secretagogue (*n*=43)    **0.416**    **0.132 to 0.637**         **0.005**              **0.422**              **0.127 to 0.648**         **0.006**                            

  Any secretagogue (*n*=54)   −0.158       −0.409 to 0.114            0.249                  −0.183                 −0.436 to 0.098            0.196                                

                                                                                                                                                                                      

  CCL-2\                      IL-1β        All subjects (*n*=291)     −0.037                 −0.151 to 0.078        0.529                      −0.036        −0.151 to 0.080        0.545
  (MCP-1)                                                                                                                                                                           

  Controls (*n*=194)          −0.008       −0.148 to 0.133            0.916                  −0.016                 −0.158 to 0.126            0.821                                

  No secretagogue (*n*=43)    −0.051       −0.346 to 0.253            0.744                  −0.062                 −0.366 to 0.255            0.703                                

  Any secretagogue (*n*=54)   −0.104       −0.362 to 0.168            0.450                  −0.067                 −0.336 to 0.213            0.639                                

                                                                                                                                                                                      

  CCL-2\                      IL-1Ra       All subjects (*n*=291)     −0.014                 −0.129 to 0.101        0.815                      −0.011        −0.127 to 0.104        0.849
  (MCP-1)                                                                                                                                                                           

  Controls (*n*=194)          −0.007       −0.148 to 0.134            0.923                  −0.004                 −0.146 to 0.138            0.953                                

  No secretagogue (*n*=43)    −0.023       −0.321 to 0.280            0.885                  −0.032                 −0.340 to 0.282            0.844                                

  Any secretagogue (*n*=54)   0.092        −0.180 to 0.351            0.507                  0.075                  −0.205 to 0.343            0.600                                

                                                                                                                                                                                      

  CCL-2\                      TNF-α        All subjects (*n*=291)     −0.013                 −0.128 to 0.102        0.824                      −0.008        −0.123 to 0.108        0.899
  (MCP-1)                                                                                                                                                                           

  Controls (*n*=194)          −0.001       −0.142 to 0.140            0.987                  −0.018                 −0.159 to 0.125            0.808                                

  No secretagogue (*n*=43)    −0.055       −0.350 to 0.249            0.722                  −0.040                 −0.347 to 0.275            0.805                                

  Any secretagogue (*n*=54)   0.127        −0.146 to 0.382            0.357                  0.155                  −0.126 to 0.413            0.273                                

                                                                                                                                                                                      

  CCL-2\                      IL-6         All subjects (*n*=291)     0.010                  −0.105 to 0.124        0.870                      0.007         −0.109 to 0.122        0.910
  (MCP-1)                                                                                                                                                                           

  Controls (*n*=194)          0.015        −0.126 to 0.156            0.831                  0.016                  −0.126 to 0.158            0.825                                

  No secretagogue (*n*=43)    0.002        −0.298 to 0.303            0.987                  0.005                  −0.307 to 0.316            0.975                                

  Any secretagogue (*n*=54)   −0.165       −0.414 to 0.108            0.230                  −0.122                 −0.385 to 0.159            0.392                                

                                                                                                                                                                                      

  CCL-3\                      CCL-4\       All subjects (*n*=291)     **0.267**              **0.157 to 0.371**     **\<0.001**                **0.268**     **0.157 to 0.372**     **\<0.001**
  (MIP-1α)                    (MIP-1β)                                                                                                                                              

  Controls (*n*=194)          **0.239**    **0.102 to 0.368**         **\<0.001**            **0.235**              **0.097 to 0.365**         **0.001**                            

  No secretagogue (*n*=43)    **0.551**    **0.301 to 0.731**         **\<0.001**            **0.581**              **0.329 to 0.756**         **\<0.001**                          

  Any secretagogue (*n*=54)   **0.750**    **0.603 to 0.847**         **\<0.001**            **0.737**              **0.580 to 0.842**         **\<0.001**                          

                                                                                                                                                                                      

  CCL-3\                      CCL-5\       All subjects (*n*=291)     0.091                  −0.025 to 0.204        0.122                      0.092         −0.024 to 0.205        0.119
  (MIP-1α)                    (RANTES)                                                                                                                                              

  Controls (*n*=194)          0.107        −0.035 to 0.244            0.138                  0.108                  −0.034 to 0.247            0.134                                

  No secretagogue (*n*=43)    0.014        −0.288 to 0.313            0.930                  −0.111                 −0.408 to 0.208            0.493                                

  Any secretagogue (*n*=54)   −0.086       −0.346 to 0.186            0.535                  −0.101                 −0.366 to 0.180            0.479                                

                                                                                                                                                                                      

  CCL-3\                      IL-1β        All subjects (*n*=291)     **0.151**              **0.037 to 0.261**     **0.010**                  **0.156**     **0.041 to 0.267**     **0.008**
  (MIP-1α)                                                                                                                                                                          

  Controls (*n*=194)          0.092        −0.050 to 0.229            0.203                  0.092                  −0.051 to 0.231            0.205                                

  No secretagogue (*n*=43)    **0.590**    **0.352 to 0.756**         **\<0.001**            **0.618**              **0.380 to 0.780**         **\<0.001**                          

  Any secretagogue (*n*=54)   0.093        −0.179 to 0.352            0.500                  0.088                  −0.192 to 0.355            0.536                                

                                                                                                                                                                                      

  CCL-3\                      IL-1Ra       All subjects (*n*=291)     **0.232**              **0.120 to 0.338**     **\<0.001**                **0.232**     **0.120 to 0.339**     **\<0.001**
  (MIP-1α)                                                                                                                                                                          

  Controls (*n*=194)          **0.223**    **0.085 to 0.353**         **0.002**              **0.215**              **0.076 to 0.347**         **0.003**                            

  No secretagogue (*n*=43)    **0.538**    **0.283 to 0.722**         **\<0.001**            **0.553**              **0.291 to 0.737**         **\<0.001**                          

  Any secretagogue (*n*=54)   0.247        −0.022 to 0.483            0.069                  **0.278**              **0.003 to 0.514**         **0.046**                            

                                                                                                                                                                                      

  CCL-3\                      TNF-α        All subjects (*n*=291)     **0.163**              **0.049 to 0.273**     **0.005**                  **0.170**     **0.055 to 0.280**     **0.004**
  (MIP-1α)                                                                                                                                                                          

  Controls (*n*=194)          0.112        −0.030 to 0.249            0.120                  0.110                  −0.033 to 0.248            0.129                                

  No secretagogue (*n*=43)    **0.570**    **0.325 to 0.743**         **\<0.001**            **0.625**              **0.389 to 0.784**         **\<0.001**                          

  Any secretagogue (*n*=54)   **0.313**    **0.049 to 0.536**         **0.020**              **0.301**              **0.028 to 0.533**         **0.030**                            

                                                                                                                                                                                      

  CCL-3\                      IL-6         All subjects (*n*=291)     0.106                  −0.009 to 0.219        0.070                      0.110         −0.006 to 0.223        0.062
  (MIP-1α)                                                                                                                                                                          

  Controls (*n*=194)          0.092        −0.050 to 0.230            0.202                  0.101                  −0.042 to 0.239            0.165                                

  No secretagogue (*n*=43)    0.296        −0.005 to 0.548            0.051                  **0.309**              −**0.002 to 0.566**        **0.049**                            

  Any secretagogue (*n*=54)   0.132        −0.141 to 0.386            0.340                  0.142                  −0.139 to 0.401            0.319                                

                                                                                                                                                                                      

  CCL-4\                      CCL-5\       All subjects (*n*=291)     −0.009                 −0.124 to 0.106        0.872                      −0.008        −0.123 to 0.108        0.894
  (MIP-1β)                    (RANTES)                                                                                                                                              

  Controls (*n*=194)          −0.039       −0.179 to 0.102            0.588                  −0.038                 −0.179 to 0.105            0.601                                

  No secretagogue (*n*=43)    0.185        −0.122 to 0.460            0.230                  0.205                  −0.114 to 0.485            0.201                                

  Any secretagogue (*n*=54)   −0.037       −0.302 to 0.233            0.789                  −0.055                 −0.326 to 0.224            0.700                                

                                                                                                                                                                                      

  CCL-4\                      IL-1β        All subjects (*n*=291)     **0.574**              **0.491 to 0.646**     **\<0.001**                **0.574**     **0.491 to 0.647**     **\<0.001**
  (MIP-1β)                                                                                                                                                                          

  Controls (*n*=194)          **0.217**    **0.079 to 0.347**         **0.002**              **0.217**              **0.078 to 0.348**         **0.002**                            

  No secretagogue (*n*=43)    **0.920**    **0.855 to 0.956**         **\<0.001**            **0.920**              **0.852 to 0.957**         **\<0.001**                          

  Any secretagogue (*n*=54)   0.018        −0.251 to 0.285            0.895                  0.037                  −0.241 to 0.310            0.795                                

                                                                                                                                                                                      

  CCL-4\                      IL-1Ra       All subjects (*n*=291)     **0.836**              **0.798 to 0.868**     **\<0.001**                **0.836**     **0.798 to 0.868**     **\<0.001**
  (MIP-1β)                                                                                                                                                                          

  Controls (*n*=194)          **0.875**    **0.838 to 0.905**         **\<0.001**            **0.875**              **0.838 to 0.905**         **\<0.001**                          

  No secretagogue (*n*=43)    **0.861**    **0.757 to 0.923**         **\<0.001**            **0.862**              **0.752 to 0.925**         **\<0.001**                          

  Any secretagogue (*n*=54)   **0.365**    **0.107 to 0.576**         **0.006**              **0.420**              **0.163 to 0.623**         **0.002**                            

                                                                                                                                                                                      

  CCL-4\                      TNF-α        All subjects (*n*=291)     **0.438**              **0.340 to 0.527**     **\<0.001**                **0.446**     **0.349 to 0.534**     **\<0.001**
  (MIP-1β)                                                                                                                                                                          

  Controls (*n*=194)          **0.421**    **0.298 to 0.531**         **\<0.001**            **0.430**              **0.307 to 0.539**         **\<0.001**                          

  No secretagogue (*n*=43)    **0.450**    **0.173 to 0.661**         **0.002**              **0.501**              **0.224 to 0.703**         **\<0.001**                          

  Any secretagogue (*n*=54)   0.067        −0.238 to 0.360            0.667                  **0.376**              **0.112 to 0.591**         **0.006**                            

                                                                                                                                                                                      

  CCL-4\                      IL-6         All subjects (*n*=291)     **0.334**              **0.228 to 0.433**     **\<0.001**                **0.336**     **0.230 to 0.435**     **\<0.001**
  (MIP-1β)                                                                                                                                                                          

  Controls (*n*=194)          **0.317**    **0.184 to 0.438**         **\<0.001**            **0.322**              **0.188 to 0.443**         **\<0.001**                          

  No secretagogue (*n*=43)    **0.680**    **0.477 to 0.814**         **\<0.001**            **0.693**              **0.486 to 0.826**         **\<0.001**                          

  Any secretagogue (*n*=54)   0.190        −0.082 to 0.436            0.165                  0.217                  −0.063 to 0.464            0.123                                

                                                                                                                                                                                      

  CCL-5\                      IL-1β        All subjects (*n*=291)     0.037                  −0.079 to 0.151        0.535                      0.040         −0.076 to 0.155        0.500
  (RANTES)                                                                                                                                                                          

  Controls (*n*=194)          0.081        −0.060 to 0.220            0.258                  0.088                  −0.055 to 0.227            0.225                                

  No secretagogue (*n*=43)    0.056        −0.249 to 0.350            0.722                  0.065                  −0.251 to 0.369            0.687                                

  Any secretagogue (*n*=54)   0.095        −0.178 to 0.353            0.494                  0.098                  −0.182 to 0.364            0.489                                

                                                                                                                                                                                      

  CCL-5\                      IL-1Ra       All subjects (*n*=291)     0.008                  −0.107 to 0.123        0.895                      0.008         −0.107 to 0.124        0.888
  (RANTES)                                                                                                                                                                          

  Controls (*n*=194)          0.011        −0.130 to 0.152            0.874                  0.013                  −0.129 to 0.155            0.857                                

  No secretagogue (*n*=43)    0.052        −0.252 to 0.347            0.739                  0.040                  −0.275 to 0.347            0.804                                

  Any secretagogue (*n*=54)   −0.093       −0.352 to 0.179            0.502                  −0.123                 −0.386 to 0.158            0.386                                

                                                                                                                                                                                      

  CCL-5\                      TNF-α        All subjects (*n*=291)     −0.064                 −0.178 to 0.051        0.274                      −0.047        −0.162 to 0.069        0.422
  (RANTES)                                                                                                                                                                          

  Controls (*n*=194)          −**0.146**   −**0.281 to** −**0.005**   **0.042**              −**0.143**             −**0.279 to** −**0.001**   **0.048**                            

  No secretagogue (*n*=43)    0.067        −0.238 to 0.360            0.667                  0.089                  −0.229 to 0.390            0.582                                

  Any secretagogue (*n*=54)   0.104        −0.168 to 0.362            0.451                  0.103                  −0.178 to 0.368            0.470                                

                                                                                                                                                                                      

  CCL-5\                      IL-6         All subjects (*n*=291)     0.051                  −0.065 to 0.165        0.388                      0.047         −0.069 to 0.161        0.430
  (RANTES)                                                                                                                                                                          

  Controls (*n*=194)          0.043        −0.098 to 0.183            0.546                  0.042                  −0.100 to 0.183            0.562                                

  No secretagogue (*n*=43)    0.038        −0.266 to 0.334            0.810                  0.052                  −0.264 to 0.358            0.749                                

  Any secretagogue (*n*=54)   0.126        −0.147 to 0.381            0.362                  0.166                  −0.115 to 0.422            0.242                                
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Significant correlations are displayed in bolded text. The differences that are only significant in either adjusted or unadjusted correlations are further denoted by an outline. Chemokine ligand 2, CCL-2 (monocyte chemoattractant protein 1, MCP-1); chemokine ligand 3, CCL-3 (macrophage inflammatory protein 1α, MIP-1α); chemokine ligand 4, CCL-4 (macrophage inflammatory protein 1β, MIP-1β); chemokine ligand 5, CCL-5 (regulated on activation normal T cell expressed and secreted, RANTES); tumor necrosis factor α, TNF-α; interleukin 1β, IL-1β; interleukin 1β receptor antagonist, IL-1Ra; interleukin 6, IL-6.
